MLND · Millendo Therapeutics, Inc

-

Please sign in to comment on MLND

1 Comment

Admin

4 years, 1 month ago

Millendo Therapeutics, Inc is currently in a long term downtrend where the price is trading 43.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Millendo Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 100.3% to $36K since the same quarter in the previous year.

Finally, its free cash flow grew by 314.4% to $25M since the same quarter in the previous year.

Based on the above factors, Millendo Therapeutics, Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US87978U1088

Market Cap	20M
Dividend Yield	0.0%
Beta	0.48
PE Ratio	None
Target Price	2

ABOUT

Millendo Therapeutics, Inc

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

MLND · Millendo Therapeutics, Inc

-

Millendo Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Millendo Therapeutics, Inc using a moving average strategy